Keywords: Avanda restrictions, Type 2 diabetes, GlaxoSmithKline, Merck & Co, Eli Lilly, Novo Nordisk, Januvia, Byetta, Victoza

Impact of Avandia restrictions could benefit Januvia, Byetta and Victoza, US physician survey reveals

Article | 07 October 2010

Print This

Following the European Medicines Agency (EMEA) decision last month to suspend the marketing authorization for UK drug giant GlaxoSmithKline’ ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in